Relmada Therapeutics, Inc. (NASDAQ:RLMD)
| Market Cap | 344.54M+38.6% |
| Revenue (ttm) | 0 |
| Net Income | -61.93M+8.7% |
| EPS | -0.92+58.6% |
| Shares Out | 106.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 775,829 |
| Open | 3.37 |
| Previous Close | 3.27 |
| Day's Range | 3.21 - 3.37 |
| 52-Week Range | 2.15 - 8.00 |
| Beta | 0.45 |
| Analysts | Buy |
| Price Target | 12.00(+271.52%) |
| Earnings Date | Nov 12, 2026 |
RELMADA THERAPEUTICS, INC. has a live Insider Score.
Scored on 4 qualifying trades from 2 insiders in the last 90 days.
About RLMD
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Nov 12, 2026Earnings report
Ask Barron about RLMD
$RLMD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RLMD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RLMD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RLMD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RLMD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RLMD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RLMD
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $11.95M |
| IWMiShares Russell 2000 ETF | $7.77M |
| VXFVanguard Extended Market ETF | $4.16M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $3.83M |
| IWOiShares Russell 2000 Growth ETF | $2.85M |
| PSILAdvisorShares Psychedelics ETF | $2.08M |
Estimated from each fund’s disclosed top holdings × AUM
RLMD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from RLMD’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score